Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7622671 | 0.71 | CHRM1 (0.43) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL16000128 | 0.70 | CHRM2 (0.50) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL321052 | 0.69 | — | — | |
| SCHEMBL8434420 | 0.69 | CHRM2 (0.48) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL18535349 | 0.67 | CHRM2 (0.35) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL6237602 | 0.67 | CHRM2 (0.44) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL28488909 | 0.66 | CHRM2 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL15218741 | 0.66 | CHRM2 (0.42) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL18535351 | 0.65 | CHRM2 (0.38) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL18334449 | 0.65 | CHRM2 (0.46) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609644-B2 | Amino derivatives of androstanes and androstenes as medicaments for cardiovascular disorders | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2013-12-17 | — | — | US | disclosed |
| EP-2004668-B1 | AMINO DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS | SIGMA TAU IND FARMACEUTI (IT) | 2013-03-13 | — | — | EP | disclosed |
| US-20110053902-A1 | AMINO DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053902-A1 | AMINO DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS | PKD1, ATP1A2, ATP1A1 | CHRM2 4202/4885CHRM4 4425/4885CHRM5 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.